Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/significance-of-high-density-lipoprotein-cholesterol-in-cardiovascular-HBJXYTChvn
References (116)
-
Bezafibrate study (2000)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease.Circulation, 102 1
-
P. Bowen, J. Guyton (2000)
Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterolCurrent Atherosclerosis Reports, 2
-
R.S. Elkeles, J.R. Diamond, C. Poulter (1998)
Cardiovascular outcomes in type 2 diabetesDiabetes Care, 21
-
H.N. Ginsberg (1998)
Lipoprotein physiologyEndocrinol Metab Clin North Am, 27
-
A. Tonkin, P. Alyward, D. Colquhoun, P. Glasziou, P. Harris, D. Hunt, A. Keech, S. MacMahon, P. Magnus, D. Newel, P. Nestel, N. Sharpe, J. Shaw, R. Simes, P. Thompson, A. Thompson, M. West, H. White, S. Simes, W. Hague, S. Caleo, Jane Hall, Andrew Martin, S. Mulray, P. Barter, L. Beilin, R. Collins, J. McNeil, P. Meier, H. Willimott, D. Smithers, P. Wallace, J. Baker, M. Hobbs, D. Sullivan, N. Anderson, G. Hankey, J. Watson, M. Arulchelvam, S. Chup, J. Daly, J. Hanna, A. Leach, M. Lee, J. Loughhead, H. Lundie-Jenkin, J. Morrison, S. Netting, A. Nguyen, H. Pater, R. Philip, G. Pinna, D. Rattos, S. Ryerson, V. Sazhin, R. Walsh, A. Claque, M. Mackie, J. Yallop, K. Boss, M. Shepard, J. Leach, M. Gandy, J. Joughin, J. Seabrook, R. Abraham, J. Allen, F. Bates, I. Beinart, E. Breed, D. Brown, N. Bunyan, D. Calvert, T. Campbell, D. Condon‐Paoloni, B. Conway, L. Coupland, J. Crowe, N. Cunio, B. Cuthbert, N. Cuthbert, S. D'arcy, P. Davidson, B. Dwyer, J. England, C. Friend, G. Fulcher, S. Grant, K. Hellestrand, M. Kava, L. Kritharides, D. McGill, H. McKee, A. Mclean, M. Neaverson, G. Nelson, M. O'Neill, C. Onuma, F. O'Reilly (1998)
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.The New England journal of medicine, 339 19
-
A. Olsson, J. Mcmurray, G. Thorgeirsson, C. Spaulding, J. Slattery, K. Pyörälä, O. Faergeman, R. Wright, Kåre Berg, L. Wilhelmsen, T. Pedersen, T. Miettinen, H. White, J. Kjekshus, M. Gnant (1994)
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994.Atherosclerosis. Supplements, 5 3
-
X. Pintó, J.F. Meco, E. Corbella (2003)
Programa de prevención secundaria de la arteriosclerosis del hospital universitario de Bellvitge: resultados principales y predictores del curso clínicoMed Clin (Barc.), 120
-
J.R. Downs, M. Clearfield, S. Weiss (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levelsJAMA, 279
-
J. Downs, M. Clearfield, S. Weis, E. Whitney, D. Shapiro, P. Beere, A. Langendorfer, E. Stein, W. Kruyer, A. Gotto (1998)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA, 279 20
-
K. Mayer, M. Dubé, D. Sprecher, W. Henry, J. Aberg, F. Torriani, H. Hodis, J. Schouten, Jules Levin, G. Myers, R. Zackin, T. Nevin, J. Currier (2000)
Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: Recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 31 5
-
M. Criqui, B. Golomb (1998)
Epidemiologic aspects of lipid abnormalities.The American journal of medicine, 105 1A
-
I. Plaza, R.P. Mariscal, M.T. Muñoz (1990)
Estudio de Fuenlabrada: asociaciń entre los niveles de lípidos y lipoproteínas en niños y adolescentes con la prevalencia de cardiopatía isquémica en sus familiaresRev Esp Cardiol, 43
-
T. Gordon, W. Kannel (1982)
Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application.American heart journal, 103 6
-
P. Durrington (1995)
Hyperlipidaemia : diagnosis and management -
Bang-Hun Lee (1997)
Treatment of Hypertension: Drug TherapyKorean Circulation Journal, 27
-
(2000)
Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) StudyCirculation, 102
-
S. Grundy (2002)
Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.Circulation, 106 20
-
D. Wood, G. Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä (1998)
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.Atherosclerosis, 140 2
-
J. Fruchart, P. Duriez (2002)
HDL and triglyceride as therapeutic targetsCurrent Opinion in Lipidology, 13
-
P. González-Santos, M. Abarca, F. Aguado (1997)
Metabolismo Lipídico -
G. Assmann, P. Cullen, H. Schulte (1998)
The Münster Heart Study (PROCAM). Results of follow-up at 8 years.European heart journal, 19 Suppl A
-
P.S. Sever, B. Dahlof, N.R. Poulter (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial, Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialLancet, 361
-
J. Pedro-botet, M. Sentí, J. Rubiés-prat, A. Pelegri, R. Romero (1996)
When to treat dyslipidaemia of patients with chronic renal failure on haemodialysis? A need to define specific guidelinesNephrology Dialysis Transplantation, 11
-
T. Pearson, S. Blair, S. Daniels, R. Eckel, J. Fair, S. Fortmann, B. Franklin, L. Goldstein, P. Greenland, S. Grundy, Yuling Hong, N. Miller, R. Lauer, I. Ockene, R. Sacco, J. Sallis, Sidney Smith, N. Stone, K. Taubert (2002)
AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee.Circulation, 106 3
-
J. Dipalma, W. Thayer (1991)
Use of niacin as a drug.Annual review of nutrition, 11
-
K. Pyörala, T.R. Pedersen, J. Kjekshus (1997)
The Scandinavian Simvastatin Survival Study (4S) Group. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart diseaseDiabetes Care, 20
-
B. Kinosian, H. Glick, G. Garland (1994)
Cholesterol and Coronary Heart Disease: Predicting Risks by Levels and RatiosAnnals of Internal Medicine, 121
-
S.G. Thompson, S.D. Pyke, D.A. Word (1996)
Using a coronary risk store for screening and intervention in general practice: British Family Heart StudyJ Cardiovasc Risk, 3
-
S. Grover, C. Palmer, L. Coupal (1994)
Serum lipid screening to identify high-risk individuals for coronary death. The results of the Lipid Research Clinics prevalence cohort.Archives of internal medicine, 154 6
-
K. Packard, J. Backes, T. Lenz, R. Wurdeman, C. Destache, D. Hilleman (2002)
Comparison of Gemfibrozil and Fenofibrate in Patients with Dyslipidemic Coronary Heart DiseasePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 22
-
S. Wannamethee, A. Shaper, S. Ebrahim (2000)
HDL-Cholesterol, total cholesterol, and the risk of stroke in middle-aged British men.Stroke, 31 8
-
J. Marrugat, R. Elosúa, M. Covas, Luis Molina, Juan Rubiés-Prat (1996)
Amount and intensity of physical activity, physical fitness, and serum lipids in men. The MARATHOM Investigators.American journal of epidemiology, 143 6
-
H. Lakka, D. Laaksonen, T. Lakka, L. Niskanen, E. Kumpusalo, J. Tuomilehto, J. Salonen (2002)
The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men.JAMA, 288 21
-
A. Chobanian, G. Bakris, H. Black, W. Cushman, L. Green, J. Izzo, Daniel Jones, B. Materson, S. Oparil, J. Wright, E. Roccella (2003)
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.JAMA, 289 19
-
J. Pekkanen, J. Pekkanen, S. Linn, G. Heiss, C. Suchindran, A. Leon, B. Rifkind, H. Tyroler (1990)
Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.The New England journal of medicine, 322 24
-
K. Alberti, P. Zimmet (1998)
Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 15
-
M. Stampfer, F. Sacks, S. Salvini, W. Willett, C. Hennekens (1991)
A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.The New England journal of medicine, 325 6
-
Diabetes Investigators (2001)
Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised studyThe Lancet, 357
-
I. Goldberg (2001)
Diabetic Dyslipidemia: Causes and ConsequencesThe Journal of Clinical Endocrinology and Metabolism, 86
-
G. Reaven (2002)
Metabolic Syndrome: Pathophysiology and Implications for Management of Cardiovascular DiseaseCirculation: Journal of the American Heart Association, 106
-
M. Corti, J. Guralnik, M. Salive, T. Harris, T. Field, R. Wallace, L. Berkman, T. Seeman, R. Glynn, C. Hennekens, R. Havlik (1995)
HDL cholesterol predicts coronary heart disease mortality in older persons.JAMA, 274 7
-
K. Pyôrâlà, T. Pedersen, J. Kjekshus, O. Faergeman, A. Olsson, G. Thorgeirsson (1997)
Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)Diabetes Care, 20
-
S. Nissen, T. Tsunoda, E. Tuzcu, P. Schoenhagen, C. Cooper, M. Yasin, G. Eaton, M. Lauer, W. Sheldon, C. Grines, S. Halpern, T. Crowe, J. Blankenship, R. Kerensky (2003)
Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.JAMA, 290 17
-
Guy Backer(Chairperson), E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cífková, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia, V. Cats, K. Orth-Gomér, J. Perk, K. Pyörälä, J. Rodicio, S. Sans, V. Sansoy, U. Sechtem, S. Silber, T. Thomsen, D. Wood (2003)
European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)European Journal of Preventive Cardiology, 10
-
B. Balkau, M. Charles (1999)
Comment on the provisional report from the WHO consultationDiabetic Medicine, 16
-
M. Frick, M. Syvänne, M. Nieminen, H. Kauma, S. Majahalme, V. Virtanen, Kesäniemi Ya, A. Pasternack, M. Taskinen (1997)
Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.Circulation, 96 7
-
S. Penzak, S. Chuck (2000)
Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment.Scandinavian journal of infectious diseases, 32 2
-
H. Rubins, S. Robins, D. Collins, C. Fye, James Anderson, M. Elam, F. Faas, E. Linares, E. Schaefer, G. Schectman, T. Wilt, J. Wittes (1999)
Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.The New England journal of medicine, 341 6
-
J. Frohlich, G. Fodor, R. McPherson (1998)
Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim reportCan J Cardiol, 14
-
S. Smith, S. Blair, R. Bonow, L. Brass, M. Cerqueira, K. Dracup, V. Fuster, A. Gotto, S. Grundy, N. Miller, A. Jacobs, D. Jones, R. Krauss, L. Mosca, I. Ockene, R. Pasternak, T. Pearson, M. Pfeffer, R. Starke, K. Taubert (2001)
AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.Journal of the American College of Cardiology, 38 5
-
M. Dubé (2000)
Disorders of glucose metabolism in patients infected with human immunodeficiency virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 31 6
-
A Dattilo, P Kris-Etherton (1992)
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis.The American journal of clinical nutrition, 56 2
-
J. Badimón, L. Badimón, V. Fuster (1990)
Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.The Journal of clinical investigation, 85 4
-
J. Cleeman (1989)
The National Cholesterol Education Program.Clinics in laboratory medicine, 9 1
-
I. Pérez (2003)
Estado actual de los programas de prevención secundaria y rehabilitación cardíaca en EspañaRevista Espanola De Cardiologia, 56
-
R.W. Clark, T.A. Sutfin, R.B. Ruggeri (2004)
Raising high density lipoprotein in humans through inhibition of cholesteryl ester transfer proteinArterioscler Thromb Vasc Biol, 24
-
J.A. Balfour, D. McTavish, R.C. Heel (1990)
Fenofibrate: a review of its pharmacodynamic and pharmacokinetics properties and therapeutic use in dyslipidaemiaDrugs, 40
-
H. Ginsberg (2000)
Nonpharmacologic management of low levels of high-density lipoprotein cholesterol.The American journal of cardiology, 86 12A
-
S. Thompson, S. Pyke, D. Wood (1996)
Using a Coronary Risk Score for Screening and Intervention in General PracticeEuropean Journal of Cardiovascular Prevention & Rehabilitation, 3
-
J.C. Fruchart, H.B. Brewer, E. Leitersdorf (1998)
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart diseaseAm J Cardiol, 81
-
W.B. Kannel (1996)
Atherosclerosis and coronary artery disease -
J. Marrugat, R. Elosua, M.-I. Covas (1996)
Amount and intensity of physical activity, physical fitness, and serum lipids in menAm J Epidemiol, 143
-
M. Frick, Olli Elo, K. Haapa, O. Heinonen, P. Heinsalmi, Pekka Helo, J. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, H. Mäenpää, M. Mälkönen, M. Mänttäri, S. Norola, A. Pasternack, J. Pikkarainen, M. Romo, T. Sjöblom, E. Nikkilä (1987)
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.The New England journal of medicine, 317 20
-
M. Stampfer, R. Krauss, Jing Ma, P. Blanche, L. Holl, F. Sacks, C. Hennekens (1996)
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.JAMA, 276 11
-
M. Austin, J. Hokanson, K. Edwards (1998)
Hypertriglyceridemia as a cardiovascular risk factor.The American journal of cardiology, 81 4A
-
R. Goldberg, M. Mellies, F. Sacks, L. Moye, B. Howard, W. Howard, B. Davis, T. Cole, M. Pfeffer, E. Braunwald (1998)
Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.Circulation, 98 23
-
F. Perez-Jimenez, P. Castro, J. López-Miranda, E. Paz-Rojas, A. Blanco, F. López-Segura, Francisco Velasco, Carmen Marin, F. Fuentes, J. Ordovás (1999)
Circulating levels of endothelial function are modulated by dietary monounsaturated fat.Atherosclerosis, 145 2
-
Jiri Frohlich, G. Fodor, R. McPherson, J. Genest, N. Langner (1998)
Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada.The Canadian journal of cardiology, 14 Suppl A
-
(2001)
Executive summary of the third report of the National Cholesterol Education Program (NCEP)JAMA, 285
-
W. Castelli, R. Garrison, P. Wilson, R. Abbott, S. Kalousdian, W. Kannel (1986)
Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.JAMA, 256 20
-
Sidney Smith, S. Blair, R. Bonow, L. Brass, M. Cerqueira, K. Dracup, V. Fuster, A. Gotto, S. Grundy, N. Miller, A. Jacobs, Daniel Jones, Ronald Krauss, L. Mosca, I. Ockene, R. Pasternak, T. Pearson, M. Pfeffer, R. Starke, K. Taubert (2001)
AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology.Circulation, 104 13
-
J.J. Badimon, L. Badimon, V. Fuster (1990)
Regression of atherosclerosis lesions by HDL plasma fraction in the cholesterol-fed rabbitJ Clin Invest, 85
-
W. Friedewald, R. Levy, D. Fredrickson (1972)
Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clinical chemistry, 18 6
-
J. Salonen, R. Salonen, K. Seppanen, R. Rauramaa, J. Tuomilehto (1991)
HDL, HDL2, and HDL3 Subfractions, and the Risk of Acute Myocardial Infarction: A Prospective Population Study in Eastern Finnish MenCirculation, 84
-
J. Fruchart, J. Fruchart, H. Brewer, E. Leitersdorf, G. Assmann, M. Brochier, G. Brown, C. Calvo, R. Carmena, R. Češka, William Loy-Soong, J. Davignon, A. Gotto, S. Grundy, A. Hamsten, A. Keech, Yuji Matsuzawa, Josef Patch, R. Paoletti, K. Rašlová, V. Smirnov, G. Steiner, G. Thompson, Jun Zhu (1998)
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group.The American journal of cardiology, 81 7
-
(2000)
Control de la colesterolemia en España 2000: un instrumente para la prevención cardiovascular -
G.M. Keating, D. Ormrod (2002)
Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemiaDrugs, 62
-
I. Plaza, R. Mariscal, M. Muñoz, J. Ros-Jellici, D. López, R. madero, I. Hidalgo, M. Ceñal, J. Baeza, A. Cobaleda (1990)
[Fuenlabrada study: lipid and lipoprotein levels in children and adolescents associated with ischemic cardiopathy prevalence among their relatives].Revista espanola de cardiologia, 43 4
-
(2002)
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation, 106
-
P. Zimmet, K. Alberti, J. Shaw (2001)
Global and societal implications of the diabetes epidemicNature, 414
-
For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group -
R. Conroy, K. Pyörälä, A. Fitzgerald, S. Sans, A. Menotti, G. Backer, D. Bacquer, P. Ducimetière, P. Jousilahti, U. Keil, I. Njølstad, R. Oganov, T. Thomsen, H. Tunstall-Pedoe, A. Tverdal, H. Wedel, P. Whincup, L. Wilhelmsen, I. Graham, I. Graham (2003)
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.European heart journal, 24 11
-
V. Mooser, A. Carr (2001)
Antiretroviral therapy-associated hyperlipidaemia in HIV diseaseCurrent Opinion in Lipidology, 12
-
P. Koskinen, M. Mänttäri, V. Manninen, J. Huttunen, O. Heinonen, M. Frick (1992)
Coronary Heart Disease Incidence in NIDDM Patients In The Helsinki Heart StudyDiabetes Care, 15
-
U. Goldbourt, S. Yaari, J. Medalie (1997)
Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men.Arteriosclerosis, thrombosis, and vascular biology, 17 1
-
(2000)
The ILIB lipid handbook for clinical practice: blood lipids and coronary heart disease -
O. Stein, Y. Stein (1999)
Atheroprotective mechanisms of HDL.Atherosclerosis, 144 2
-
V. Kamanna, M. Kashyap (2000)
Mechanism of action of niacin on lipoprotein metabolismCurrent Atherosclerosis Reports, 2
-
(2001)
update: a statement for healthcare professionals from the American Heart Association and the American College of CardiologyCirculation, 104
-
N. Kaplan (2002)
Kaplan's Clinical Hypertension -
B. Isomaa, P. Almgren, T. Tuomi, B. Forsén, Kaj Lahti, M. Nissen, M. Taskinen, L. Groop (2001)
Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diabetes care, 24 4
-
AndrewJ. Coats (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 360
-
J. Guichard, P. Blouquin, Yi Qing (2000)
A New Formulation of Fenofibrate: Suprabioavailable TabletsCurrent Medical Research and Opinion, 16
-
G. Backer, E. Ambrosioni, K. Borch-Johnsen (2003)
European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical PracticeEur Heart J, 24
-
F. Laporte, S. Halimi (2000)
Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels.Diabetes care, 23 11
-
A. Hardman (1999)
Role of exercise and weight loss in maximizing LDL cholesterol reductionEuropean Heart Journal Supplements, 1
-
T.A. Pearson, S.N. Blair, S.R. Daniels (2002)
AHA guidelines for primary prevention of cardiovascular disease and stroke, 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseasesCirculation, 106
-
J. Marrugat, Pascual Solanas, R. D'Agostino, Lisa Sullivan, J. Ordovás, F. Cordón, R. Ramos, J. Sala, R. Masiá, I. Rohlfs, Roberto Elosua, William Kannel (2003)
Estimación del riesgo coronario en España mediante la ecuación de Framingham calibradaRevista Espanola De Cardiologia, 56
-
R. Elkeles, J. Diamond, C. Poulter, S. Dhanjil, A. Nicolaides, Shahid Mahmood, W. Richmond, H. Mather, P. Sharp, M. Feher (1998)
Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) StudyDiabetes Care, 21
-
Henrik Schultz (1998)
Tobacco or health: A global status report.Annals of Saudi medicine, 18 2
-
Weiquan Lu, H. Resnick, K. Jablonski, K. Jones, A. Jain, W. Howard, D. Robbins, B. Howard (2003)
Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study.Diabetes care, 26 1
-
G. Assmann, H. Schulte, A. Eckardstein, Yadong Huang (1996)
High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport.Atherosclerosis, 124 Suppl
-
D. Gordon, J. Probstfield, R. Garrison, J. Neaton, W. Castelli, James Knoke, D. Jacobs, S. Bangdiwala, H. Tyroler (1989)
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.Circulation, 79 1
-
R. Clark, T. Sutfin, R. Ruggeri, Ann Willauer, E. Sugarman, G. Magnus-Aryitey, P. Cosgrove, T. Sand, R. Wester, John Williams, M. Perlman, M. Bamberger (2004)
Raising High-Density Lipoprotein in Humans Through Inhibition of Cholesteryl Ester Transfer Protein: An Initial Multidose Study of TorcetrapibArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 24
-
(1987)
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. -
B. Balkau, M.A. Charles (1999)
Comment on the provisional report from the WHO consultation: the European Group for the Study of Insulin Resistance (EGIR)Diabetic Medicine, 16
-
C. Wanner (2000)
Importance of hyperlipidaemia and therapy in renal patients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 15 Suppl 5
-
I. Plaza Pérez (2003)
Programas de prevención secundaria y rehabilitatión cardiaca en EspañaRev Esp Cardiol, 56
-
F. Sacks (2002)
The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations.The American journal of cardiology, 90 2
-
F.M. Sacks (2002)
The role of high density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. The Expert Group on HDL CholesterolAm J Cardiol, 90
-
S. Yusuf (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. CommentaryThe Lancet, 360
-
G. Assmann, P. Cullen, H. Schulte (2002)
Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) StudyCirculation: Journal of the American Heart Association, 105
-
C. Ericsson, Jan Nilsson, Lars Grip, B. Svane, Anders Hamsten (1997)
Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]).The American journal of cardiology, 80 9
-
D. Day (2001)
Population-based screening with the Coronary Heart Disease Risk Factor Calculator®Advances in Therapy, 18
-
S. Haffner (1998)
Management of Dyslipidemia in Adults With DiabetesDiabetes Care, 21
-
J. Morgan, D. Capuzzi, R. Baksh, C. Intenzo, C. Carey, D. Reese, K. Walker (2003)
Effects of extended-release niacin on lipoprotein subclass distribution.The American journal of cardiology, 91 12
- Publisher
- Springer Journals
- Copyright
- Copyright © 2004 by Adis Data Information BV
- Subject
- Pharmacy; Pharmacy
- ISSN
- 1175-3277
- eISSN
- 1179-187X
- DOI
- 10.2165/00129784-200404050-00003
- pmid
- 15449972
- Publisher site
- See Article on Publisher Site
Abstract
In the approach to lipid-related risk factors for cardiovascular diseases, serum high density lipoprotein-cholesterol (HDL-C) levels bear a particular significance as this lipoprotein is considered to be an antiatherogenic factor mainly, but not only, because of its influence and impact on reverse cholesterol transport. Hence the need and requirement to consider serum HDL-C levels for both primary and secondary prevention of cardiovascular disease. A particularly important aspect is the association of the ‘low HDL syndrome’ with the metabolic syndrome.
Journal
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 17, 2012